Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Acp 103
2. Acp-103
3. Acp103
4. Bis(1-(4-fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2r,3r)-2,3-dihydroxybutanedioate
5. N-(4-fluorophenylmethyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide
6. Nuplazid
7. Pimavanserin Tartrate
8. Urea, N-((4-fluorophenyl)methyl)-n-(1-methyl-4-piperidinyl)-n'-((4-(2-methylpropoxy)phenyl)methyl)-, (2r,3r)-2,3-dihydroxybutanedioate (2:1)
1. 706779-91-1
2. Acp-103
3. 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea
4. Pimavanserin [inn]
5. Pimavanserin Free Base
6. Jz963p0dik
7. 706779-91-1 (free Base)
8. 1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
9. N-(4-fluorophenylmethyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl) Carbamide
10. Unii-jz963p0dik
11. N-(4-fluorophenylmethyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide
12. 706782-28-7
13. Pimanavserin
14. Methyltrimethylacetate
15. Ac-5273
16. Pimavanserin [mi]
17. Pimavanserin(acp-103)
18. Pimavanserin [who-dd]
19. Schembl675165
20. Nuplazid (proposed Trade Name)
21. Gtpl8423
22. Chembl2111101
23. Dtxsid90990906
24. Chebi:133017
25. Bdbm139370
26. Hms3742a03
27. Bcp11618
28. Ex-a4895
29. Mfcd09953792
30. Zinc16159083
31. Akos015902593
32. Cs-3378
33. Db05316
34. Me-0240
35. Sb16963
36. Ncgc00390656-01
37. Ncgc00390656-02
38. Hy-14557
39. B8019
40. Ft-0653701
41. A14434
42. 779p911
43. A836958
44. J-503297
45. Q7194603
46. N-[(4-fluorophenyl)methyl]-n-(1-methyl-4-piperidinyl)-n'-[[4-(2-methylpropoxy)phenyl]methyl]urea;
47. N-[(4-fluorophenyl)methyl]-n-(1-methylpiperidin-4-yl)-n'-{[4-(2-methylpropoxy)phenyl]methyl}urea
Molecular Weight | 427.6 g/mol |
---|---|
Molecular Formula | C25H34FN3O2 |
XLogP3 | 4.5 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 8 |
Exact Mass | 427.26350550 g/mol |
Monoisotopic Mass | 427.26350550 g/mol |
Topological Polar Surface Area | 44.8 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 523 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Pimavanserin is indicated for the treatment of hallucinations and delusions associated with Parkinsons disease psychosis.
Treatment of schizophrenia and other psychotic disorders
Pimavanserin's unique actions on serotonin receptors improve symptoms of hallucinations and delusions associated with Parkinson's disease. In clinical studies, 80.5% of individuals treated with pimavanserin reported improvement in symptoms. Pimavanserin does not worsen motor functioning in patients with Parkinson's disease psychosis.
Antiparkinson Agents
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
Serotonin 5-HT2 Receptor Antagonists
Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes. (See all compounds classified as Serotonin 5-HT2 Receptor Antagonists.)
N - Nervous system
N05 - Psycholeptics
N05A - Antipsychotics
N05AX - Other antipsychotics
N05AX17 - Pimavanserin
Absorption
The median Tmax of pimavanserin in clinical studies was 6 hours, regardless of the dose. Bioavailability of an oral tablet of pimavanserin and a solution were almost identical. The major active circulating N-desmethylated metabolite, AC-279, has a median Tmax of 6 hours.
Route of Elimination
About 0.55% of a 34 mg oral dose was excreted unchanged in the urine and 1.53% was eliminated in feces within 10 days. Less than 1% of the administered dose and its active metabolite AC-279 were recovered in urine during clinical studies.
Volume of Distribution
Following administration of a single dose of 34 mg, the average apparent volume of distribution was 2173 L in clinical studies.
Pimavanserin is mainly metabolized CYP3A4 and CYP3A5 hepatic cytochrome enzymes, and to a lesser extent by CYP2J2, CYP2D6, and other cytochrome and flavin-containing monooxygenase enzymes. CYP3A4 metabolizes pimavanserin to its major active metabolite, AC-279.
The average plasma half-lives for pimavanserin and its active metabolite (AC-279) are estimated at 57 hours and 200 hours, respectively.
Parkinson's disease psychosis (PDP) is a imbalance of serotonin and dopamine from disruption of the normal balance between the serotonergic and dopaminergic receptors and neurotransmitters in the brain. The mechanism by which pimavanserin treats hallucinations and delusions associated with Parkinsons disease psychosis is not fully established. It is possible that pimavanserin acts via inverse agonist and antagonist activity at serotonin 5-HT2A receptors with limited effects on serotonin 5-HT2C receptors. Pimavanserin is an inverse agonist and antagonist of serotonin 5-HT2A receptors with high binding affinity, demonstrating low binding affinity to serotonin 5-HT2C receptors. In addition, this drug exhibits low affinity binding to sigma 1 receptors. Pimavanserin lacks activity at muscarinic, dopaminergic, adrenergic, and histaminergic receptors, preventing various undesirable effects typically associated with antipsychotics.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Pimavanserin Tartrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pimavanserin Tartrate, including repackagers and relabelers. The FDA regulates Pimavanserin Tartrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pimavanserin Tartrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pimavanserin Tartrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pimavanserin Tartrate supplier is an individual or a company that provides Pimavanserin Tartrate active pharmaceutical ingredient (API) or Pimavanserin Tartrate finished formulations upon request. The Pimavanserin Tartrate suppliers may include Pimavanserin Tartrate API manufacturers, exporters, distributors and traders.
click here to find a list of Pimavanserin Tartrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Pimavanserin Tartrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Pimavanserin Tartrate active pharmaceutical ingredient (API) in detail. Different forms of Pimavanserin Tartrate DMFs exist exist since differing nations have different regulations, such as Pimavanserin Tartrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pimavanserin Tartrate DMF submitted to regulatory agencies in the US is known as a USDMF. Pimavanserin Tartrate USDMF includes data on Pimavanserin Tartrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pimavanserin Tartrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pimavanserin Tartrate suppliers with USDMF on PharmaCompass.
A Pimavanserin Tartrate written confirmation (Pimavanserin Tartrate WC) is an official document issued by a regulatory agency to a Pimavanserin Tartrate manufacturer, verifying that the manufacturing facility of a Pimavanserin Tartrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Pimavanserin Tartrate APIs or Pimavanserin Tartrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Pimavanserin Tartrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Pimavanserin Tartrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pimavanserin Tartrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pimavanserin Tartrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pimavanserin Tartrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pimavanserin Tartrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pimavanserin Tartrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pimavanserin Tartrate suppliers with NDC on PharmaCompass.
Pimavanserin Tartrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pimavanserin Tartrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pimavanserin Tartrate GMP manufacturer or Pimavanserin Tartrate GMP API supplier for your needs.
A Pimavanserin Tartrate CoA (Certificate of Analysis) is a formal document that attests to Pimavanserin Tartrate's compliance with Pimavanserin Tartrate specifications and serves as a tool for batch-level quality control.
Pimavanserin Tartrate CoA mostly includes findings from lab analyses of a specific batch. For each Pimavanserin Tartrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pimavanserin Tartrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Pimavanserin Tartrate EP), Pimavanserin Tartrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pimavanserin Tartrate USP).
LOOKING FOR A SUPPLIER?